Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease

Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease

Huntington's disease (HD) is an inherited progressive neurological disorder for which there is no effective therapy. It is caused by a CAG/polyglutamine repeat expansion that leads to abnormal protein aggregation and deposition in the brain. Several compounds have been shown to disrupt the aggr...

Full description

Bibliographic Details
Main Authors: Emma Hockly, Jamie Tse, Amy L. Barker, Donna L. Moolman, Jean-Luc Beunard, Adrian P. Revington, Kim Holt, Sunny Sunshine, Hilary Moffitt, Kirupa Sathasivam, Benjamin Woodman, Erich E. Wanker, Philip A.S. Lowden, Gillian P. Bates
Format: Article
Language:English
Published: Elsevier 2006-01-01
Series:Neurobiology of Disease
Subjects:
Huntington's disease
Polyglutamine
Neurodegeneration
Aggregation Inhibitor
Benzothiazole
Riluzole
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996105002056

Internet

http://www.sciencedirect.com/science/article/pii/S0969996105002056

Similar Items